粒细胞集落刺激因子治疗重症酒精性肝炎患者疗效的Meta分析*

doi:10.3969/j.issn.1672-5069.2023.02.015

Abstract

Abstract: Objective The aim of this study was to meta analyze the clinical efficacy of granulocyte colony stimulating factor (G-GSF) in treatment of patients with severe alcoholic hepatitis (SAH). Methods The PubMed, Embase, Chinese Journal Full-text Database, Wanfang Database, Chinese Science and Technology Journal Database, Chinese Medical Association digital Journal Database in Chinese and English were searched from the establishment of databases to May 2022. At the same time, we handed check related journals and conference proceedings. The randomized controlled trials (RCT) on the administration of G-CSF in the treatment of patients with SAH were analyzed to evaluate the 90-day survival rate in both G-CSF-treated and control groups, and the data were analyzed by RevMan 5.4. Results A total of 198 patients were included in 5 RCT studies obtained; at the base of conventional medical support therapy, 98 patients received G-CSF and another 100 patients received placebo; by the Meta-analysis, the 90-day survival in the G-CSF-treated group was 76.5%, much higher than 28.0% in the control group, and the difference was statistically significant (RR=2.74,95% CI: 1.96-3.83, P＜0.01); there was no significant heterogeneity among the five studies (P=0.61, I²=0%). Conclusion In patients with SAH, the 90-day survival rate is significantly improved when the G-CSF treatment is given, which needs further clinical investigation.

Key words: Severe alcoholic hepatitis, Granulocyte colony-stimulating factor, Therapy, Meta-analysis

Zhang Longyu, Mou Danlei, Li Tongzeng, et al.. Clinical efficacy of granulocyte colony stimulating factor in the treatment of patients with severe alcoholic hepatitis:a Meta-analysis[J]. Journal of Practical Hepatology, 2023, 26(2): 210-213.

References

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪肝专家委员会. 酒精性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2): 170-176.
[2] Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med, 1989, 110(9): 685-690.
[3] Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology, 1978, 75(2): 193-199.
[4] Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med, 2009, 360(26): 2758-2769.
[5] Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology, 2020, 71(1): 306-333.
[6] Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholic liver disease. Am J Gastroenterol, 2018, 113(2): 175-194.
[7] Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut, 2011, 60(2): 255-260.
[8] Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med, 2015, 372(17): 1619-1628.
[9] Singh S, Murad MH, Chandar AK, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: A systematic review and network Meta-analysis. Gastroenterology, 2015, 149(4): 958-970, e12.
[10] Vergis N, Atkinson SR, Knapp S, et al. In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA. Gastroenterology, 2017, 152(5): 1068-1077, e4.
[11] Singh V, Keisham A, Bhalla A, et al. Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis. Clin Gastroenterol Hepatol, 2018, 16(10): 1650-1656, e2.
[12] Spahr L, Lambert JF, Rubbia-Brandt L, et al. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology, 2008, 48(1): 221-229.
[13] Mark AL, Sun Z, Warren DS, et al. Stem cell mobilization is life saving in an animal model of acute liver failure. Ann Surg, 2010, 252(4): 591-596.
[14] 周培, 于淙, 渠淑云. 集落刺激因子治疗终末期酒精性肝病的临床对照研究. 肝脏, 2020, 25(5): 521-524.
[15] Shasthry SM, Sharma MK, Shasthry V, et al. Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: A double-blind randomized controlled trial. Hepatology, 2019, 70(3): 802-811.
[16] Sharma A, Setia A, Rai RR. Effect of granulocyte colony-stimulating factor (G-CSF) on mortality and complications viz. sepsis, encephalopathy, hepatorenal syndrome, and gastrointestinal bleed in severe alcoholic hepatitis: a randomized controlled study. United Eur Gastroenterol, 2017, 5: A17.
[17] Singh V, Sharma AK, Narasimhan RL, et al. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol, 2014, 109(9): 1417-1423.
[18] Singal AK, Salameh H, Singal A, et al. Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians. World J Gastrointest Pharmacol Ther, 2013, 4(2): 16-22.
[19] 张岱, 王炳元. 酒精性肝炎的诊断与挑战. 实用肝脏病杂志. 2019, 22(2): 153-155.
[20] 范文瀚, 罗怡平, 李成忠. 糖皮质激素应用于肝衰竭治疗机制及其临床时机的把握. 实用肝脏病杂志, 2020, 23(1): 7-9.
[21] Singal AK, Kamath PS, Gores GJ, et al. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol, 2014, 12(4): 555-564; quiz e31-32.
[22] Dubuquoy L, Louvet A, Lassailly G, et al. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut, 2015, 64(12): 1949-1960.
[23] Gustot T. Beneficial role of G-CSF in acute-on-chronic liver failure: effects on liver regeneration, inflammation/immunoparalysis or both? Liver Int, 2014, 34(4): 484-486.
[24] Moreau R, Rautou PE. G-CSF therapy for severe alcoholic hepatitis: targeting liver regeneration or neutrophil function? Am J Gastroenterol, 2014, 109(9): 1424-1426.
[25] Dale DC, Crawford J, Klippel Z, et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer, 2018, 26(1): 7-20.

Clinical efficacy of granulocyte colony stimulating factor in the treatment of patients with severe alcoholic hepatitis:a Meta-analysis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yin Wen, Lu Kexiang, Wang Xue, et al.. Short-term efficacy of oxymatrine and entecavir combination in the treatment of patients with serum HBeAg-positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(2): 173-176.
[2]	Wei Li, Liu Bo, Zhao Nan, et al.. Would the coincidence of nonalcoholic fatty liver diseases impact the antiviral response to enticavir therapy in patients with chronic hepatitis B? [J]. Journal of Practical Hepatology, 2023, 26(2): 181-184.
[3]	Ling Jiahui, Ni Meixin, Han Lili, et al.. Serum cytokine changes in patients with autoimmune hepatitis receiving magnesium isoglycyrrhizinate treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 214-217.
[4]	Li Yanfen, Zhang Xiaowen, Wang Yanru, et al.. Rescuing therapy of obeticholic acid and fibrates in patients with primary biliary cholangitis without complete response to ursodeoxycholic acid treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 226-229.
[5]	Xu Jing, Liu Kun, Ma Zhufang. Clinical efficacy of magnesium isoglycyrrhizinate in preventing and treating liver and kidney injuries in patients with advanced gastric cancer undergoing chemotherapy [J]. Journal of Practical Hepatology, 2023, 26(2): 234-237.
[6]	Cheng Yang, Zhang Feng, Wang Xixuan, et al.. Comparison of clinical efficacy of carvedilol and propranolol in preventing esophagogastric varices bleeding in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(2): 254-257.
[7]	Zhang Bin, Zhao Yuliang, Yan Guobei. Efficacy of hUCB-MNC and hUC-MSC transfusion in patients with decompensated hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(2): 262-265.
[8]	Zhou Qiujuan, Zhu Yiming, Ma Yuhang, et al.. Improvement of hypersplenism in patients hepatitis B cirrhosis after TIPS and PSE combination treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 266-269.
[9]	Gu Kai, Wu Xiaochen, Zhu Yiming. Single high dose of hepatic irradiation in ameliorating hepatic pain in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(2): 270-273.
[10]	Gong Cheng, Tian Yinsheng, Liu Shuang. Comparison of two-year survivals in primary liver cancer patients with spontaneous tumor rupture underwent hepatectomy at early or late operation time windows [J]. Journal of Practical Hepatology, 2023, 26(2): 274-277.
[11]	Shi Hao, Chen Yong, Luo Bin, et al.. Preoperative doxorubicin magnetic fluid targeted chemotherapy before microwave ablation in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(2): 278-281.
[12]	Yin Qiushi, Wang Xueguo, Song Qifeng. Comparison of complete laparoscopic left hemihepatectomy and traditional open laparotomy with left hepatic pedicle occlusion in treatment of patients with intrahepatic and extrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(2): 282-285.
[13]	Huang Shulun, He Shengduo, Xu Xiaoyuan, et al.. Efficacy of partial enteral nutrition and octreotide treatment for liver cirrhotic patient with chylous ascites:a case report [J]. Journal of Practical Hepatology, 2023, 26(2): 290-292.
[14]	Shen Yan, Chen Lin. Endoscopic treatment and long-term management of patients with esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2023, 26(1): 8-10.
[15]	Zhang Dan, Jiang Jianxin. Comparison of response to recombinant cytokine gene-derived protein or human interferon α-2b and entecavir combination in the treatment of patients with serum HBeAg positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(1): 27-30.